We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cell-Specific Bioorthogonal Tagging of Glycoproteins Developed

By LabMedica International staff writers
Posted on 31 Oct 2022
Print article
Image: Development of an artificial biosynthetic pathway for chemically tagged UDP-GalNAc/GlcNAc analogues (Photo courtesy of Benjamin Schumann, PhD)
Image: Development of an artificial biosynthetic pathway for chemically tagged UDP-GalNAc/GlcNAc analogues (Photo courtesy of Benjamin Schumann, PhD)

Altered glycoprotein expression is an undisputed corollary of cancer development. Understanding these alterations is paramount but hampered by limitations underlying cellular model systems. For instance, the intricate interactions between tumor and host cannot be adequately recapitulated in monoculture of tumor-derived cell lines.

Cancer is a multifactorial disease consisting of an interplay between host and tumor. Posttranslational modifications (PTMs) heavily impact the plasticity of the proteome. Glycosylation is the most complex and most abundant PTM, but challenging to probe due to the non-templated nature of glycan biosynthesis.

Chemists and Biochemists at the Imperial College London (London, UK) have developed a new method to study the proteins released by cells, which could lead to the development of new tools to track diseases including cancer. Their method identifies proteins released by a specific type of cell, even if the cells are in a complex environment with many different cell types. The method is called Bio-Orthogonal Cell line-specific Tagging of Glycoproteins (BOCTAG).

The method uses bioorthogonal chemistry or click chemistry. The chemical tag is selected so that it "clicks" with another molecule that helps the scientists isolate the desired proteins or add a fluorescent tag to them. The investigators showed that BOCTAG worked in cell cultures with multiple cell lines and in mice, where they successfully tagged proteins from specific cancer cells. This method could also be used in fields such as immunology, infectious diseases, and to better understand disease biology, particularly how tumor cells change as a result of complex interactions in the body.

Cells are equipped by transfection with an artificial biosynthetic pathway that transforms bioorthogonally tagged sugars into the corresponding nucleotide-sugars. Only transfected cells incorporate bioorthogonal tags into glycoproteins in the presence of non-transfected cells. The team employed BOCTAG as an imaging technique and to annotate cell-specific glycosylation sites in mass spectrometry-glycoproteomics using Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) equipped with a ACQUITY UPLC BEH Glycan (Waters Corporation, Milford, MA, USA). They demonstrated application in co-culture and mouse models, allowing for profiling of the glycoproteome as an important modulator of cellular function. The study was published on October 25 2022 in the journal Nature Communications.

Related Links:
Imperial College London
Waters Corporation

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more